INTRODUCTION
Idiopathic pulmonary arterial hypertension (iPAH) is a rare disease with a grim prognosis and a poorly understood pathogenesis. The disease is characterized by abnormal vascular cell proliferation that eventually obliterates the small pulmonary arteries 1 . Although hyperplasia of pulmonary artery smooth muscle cells (PA-SMCs) is considered the main component of the remodeling process in iPAH, the nature of the primary abnormality that triggers and perpetuates PA-SMC proliferation in iPAH is unclear. Whether smooth muscle hyperplasia results from inherent characteristics of PA-SMCs [2] [3] [4] [5] or from dysregulation of molecular events governing PA-SMC growth, such as signals originating from pulmonary endothelial cells (P-ECs), remains an open question 6, 7 .
The role of P-ECs in angiogenesis and remodeling is now better elucidated. A critical aspect of vessel development is maturation, during which P-ECs no longer proliferate or migrate but instead promote vessel stabilization by recruiting peri-endothelial support cells, which differentiate into smooth muscle cells 6 . Because this maturation phase is under the control of angiopoietin-1 (Ang1), which acts selectively on ECs via the Tie2 receptor 8 , one theory is that EC stimulation by Ang1 leads to the release of signaling molecules that act on smooth muscle cells 9, 10 . In accordance with a role for such a mechanism in the pulmonary circulation, it was recently shown that P-ECs stimulated with Ang1 were capable of promoting PA-SMC growth 10 . In a more recent study, we obtained evidence that serum-free medium of quiescent human P-ECs elicited marked PA-SMC proliferation, although the PECs were not previously stimulated by Ang1. Interestingly, this effect was greater with P-ECs from patients with iPAH than with P-ECs from controls, suggesting dysregulation of this mechanism in iPAH 11 . Thus, an intriguing hypothesis is that the angiopoietin/Tie2 pathway, which seems to play a role in normal vessel wall development, may be altered in iPAH, thereby leading to excessive smooth muscle proliferation.
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In the present study, we investigated the angiopoietin-1/Tie2 pathway in patients with iPAH. For this purpose, we sampled lung tissue from patients with iPAH and controls and we first investigated the expression of Ang1, Ang2, and Tie2 receptor in cultured PA-SMCs and in P-ECs, as well as in whole lung homogenates. Second, we investigated whether treatment of cultured P-ECs with Ang1 increased the growth-promoting activity of culture medium from P-ECs of patients and controls. Third, in recent studies by Sullivan and Eddahibi, serotonin (5-HT) appeared as the main P-EC-derived growth factor acting on PA-SMCs 10, 11 .
We therefore investigated whether Ang1 altered the release by P-ECs of 5-HT and other growth factors including endothelin-1 (ET-1), platelet-derived growth factor-BB (PDGF-BB), and epidermal growth factor (EGF). Because 5-HT synthesis is mediated by the enzyme tryptophan hydroxylase-1 (TPH1), and because ET-1 activation and maturation are controlled by endothelin-converting enzyme-1 (ECE-1), we also examined the effect of Ang1 on mRNA levels of these enzymes, as well as on mRNA levels of preproendothelin-1 (preproET-1). We selected patients meeting a strict definition of iPAH, since it is unclear whether the pulmonary vascular biological derangements are identical in iPAH and in associated PAH or secondary PAH.
MATERIALS AND METHODS

Tissue collection
Lung tissue was sampled at lung transplantation in 14 patients with iPAH (7 females and 7 males) and during lobectomy or pneumonectomy for a localized tumor in 15 control patients (5 females and 10 males). In the controls, transthoracic echocardiography was performed preoperatively to rule out pulmonary hypertension, and pulmonary arteries were studied at a distance from tumor areas. 
Isolation of pulmonary artery smooth muscle cells (PA-SMCs) and pulmonary microvascular endothelial cells (P-ECs)
Human PA-SMCs were cultured from explants of pulmonary arteries as previously described 12 . To determine the phenotypic characteristics of cultured PA-SMCs, the cells were assessed for expression of muscle-specific contractile and cytoskeletal proteins including smooth muscle cell α-actin, desmin and vinculin 12 . PA-SMCs were used between passages 3 and 6.
Human P-ECs were obtained by Dispase I (Roche Diagnostics, Penzbeg, Germany) digestion of a 5-cm 3 lung tissue fragment left at 37°C overnight. The suspension was filtered, plated onto 0.1% gelatin-coated wells, and grown in MCDB131 medium (Invitrogen, CergyPontoise, France) supplemented with 10% fetal bovine serum (FCS), 50 U/mL of 6 penicillin/streptomycin, 4 mM of L-glutamine, 25 mM HEPES, 10 U/mL of heparin, 1 µg/mL of ECGS, and 10 ng/mL of vascular endothelial growth factor (VEGF) (Promocell, Heidelberg, Germany). Immunomagnetic purification of P-ECs was performed using anti-PECAM-1 (CD31) monoclonal antibody-labeled DynaBeads (Dynal Biotech, Compiegne, France). To characterize the endothelial cell phenotype, P-ECs were labeled with acetylated low-density lipoprotein coupled to a fluorescent carbocyanine dye (Dil-Ac-LDL, Tebu, Le
Perray en Yvelines, France) and stained using antibodies against the endothelial cell-specific lectin Ulex europaeus agglutinin-1 (UEA-1, Sigma-Aldrich, Ayrshire, UK) 13 . Experiments were also performed using monoclonal antibodies against desmin and vimentin (Dako, Glostrup, Denmark). Cells with positive staining for Dil-Ac-LDL and UEA-1 and negative staining for desmin and vimentin were taken as endothelial cells and constituted more than 95% of our P-EC cultures. Cells were used between passages 3 and 6 11 . The homogenates were centrifuged at 4°C and the supernatants were collected. PA-SMC and P-EC homogenates were prepared using the same procedure. After determination of the protein concentration using the method of Bradford 15 , 100 µg of protein from each lung sample was resuspended in 3x Laemmli's buffer, boiled for 5 minutes, and separated on 10% Immunoreactive bands were detected using the enhanced chemiluminescence Western blotting analysis system (Amersham Pharmacia Biosciences, Buckinghamshire, UK) and quantified by laser densitometry. Relative quantification was performed by normalization with β-actin (Sigma-Aldrich CO, St Louis, USA).
Total RNA extraction
Lung Tie2 receptor Immunolocalization
Lung specimens were fixed in 4% paraformaldehyde and embedded in paraffin.
Five-micrometer sections were dewaxed and progressively rehydrated. 
PA-SMC Growth Assays
PA-SMCs in DMEM supplemented with 10% FCS were seeded at a density of 5·10 4 cells/well in 24-well plates and allowed to adhere. The cells were subjected to 48 hours of growth arrest in medium containing 0% FCS then treated with 1 ml of conditioned medium collected from P-ECs with or without Ang1 treatment (50 ng/mL). P-EC serum-free medium was obtained as follows: at the time of initiating PA-SMC growth arrest, P-ECs were seeded in 24-well plates at a density of 5·10 4 cells/well and were allowed to adhere and to grow in supplemented MCDB131 (as described above but without heparin) for 24 hours. The P-ECs were then subjected to 24 hours of growth arrest in MCDB131 medium with 0.2% FCS, with or without Ang1 treatment (50 ng/mL). PA-SMC proliferation was then assessed with or without fluoxetine (10 -6 mol/L) and with or without Bosentan (10 -6 mol/L). None of these drugs was used to treat P-ECs. PA-SMC proliferation was also assessed in response to 5% HT peak areas with reference to authentic 5-HT standards and were not corrected for recovery 17 . ET-1, EGF, and PDGF-BB concentrations in P-EC supernatant were determined by ELISA (R&D Systems, Minneapolis, MN). For assays of TPH1, preproET-1, and ECE-1 mRNAs, P-ECs were seeded and synchronized, as described above. The cells were exposed to Ang1 (50 ng/mL) for 4 hours then used for RTQ-PCR.
Statistical Analysis
All data are reported as mean±SEM. ANOVA was used for comparisons between two groups. When the ANOVA ratio reached P<0.05, the groups were compared using non-parametric Mann-Whitney U tests. P values less than 0.05 were considered statistically significant. To assess the effects of various treatments on PA-SMC growth induced by P-EC media, the non-parametric Kruskal-Wallis test was performed. When the Kruskal-Wallis test showed a significant difference, the groups were further compared using a non-parametric SNK test.
RESULTS
Angiopoietin-1, Angiopoietin-2, and Tie2 receptor expression in human lung homogenates and cultured cells
Ang1 expression as assessed by RTQ-PCR and Western blotting for mRNA and protein, respectively, on whole lung tissue homogenates and on PA-SMCs was not different in the patients with iPAH and in the controls (Figures 1 and 4) . Ang1 mRNAs were not detected in P-ECs from patients with iPAH or controls. Ang2 expression assessed by RTQ-PCR and
Western blotting was similar in lung tissue homogenates, as well as in P-ECs from patients with iPAH and controls ( Figures 2 and 4) . In contrast, Tie2 receptor expression in whole lung tissue homogenates and P-ECs was increased 3-fold to 4-fold in the iPAH patients compared to the controls (Figures 3 and 4) . About 60% of lung Tie2 receptor was phosphorylated. As shown in Figure 3 , immunohistochemical analyses revealed that Tie2 immunostaining was confined to the intima of pulmonary vessels, in both iPAH patients and controls; no staining was seen in the media. No relationship was found between hemodynamic parameters (pulmonary artery pressure and pulmonary vascular resistance) and levels of Ang1, Ang2, or Tie2 proteins in the lung.
Growth of PA-SMCs in response to serum-free media derived from cultured P-ECs with or without angiopoietin-1 pretreatment
Addition of serum-free media from cultured P-ECs to PA-SMCs from the same individual produced a marked increase in [ 3 H]thymidine incorporation ( Figure 5A ). As previously reported, the increase was larger when PA-SMCs were stimulated with media of PECs from patients with iPAH, compared to P-ECs from controls 11 . Pretreatment of P-ECs with Ang1 (50 ng/mL) increased the growth-promoting effect of P-EC culture media on PASMCs, with both P-ECs from controls and P-ECs from patients with iPAH ( Figure 5A ). To determine the contribution of ET-1 to PA-SMC growth, we tested the endothelin receptor antagonist Bosentan. As shown in Figure 5B , Bosentan treatment of PA-SMCs did not affect the total growth response of PA-SMCs to media from P-ECs previously incubated with or without Ang1. Because we previously reported that 5-HT was responsible for most of the growth-promoting effect of P-EC culture media 11 , we repeated the experiments with fluoxetine, a selective inhibitor of the 5-HT transporter, which mediates the mitogenic activity of 5-HT. As shown in Figure 5C , fluoxetine treatment of PA-SMCs significantly reduced PA-SMC growth under all study conditions. However, even in PA-SMCs treated with fluoxetine, the growth-promoting effect of media from Ang1-treated P-ECs was greater than that of media from untreated P-ECs ( Figure 5C ).
Effect of Ang1 on signal molecule release by P-ECs
The concentrations of 5-HT and ET-1 were higher in the medium of P-ECs from patients with iPAH than from controls ( Figures 6A and 6B ). In contrast, EGF and PDGF-BB concentrations did not differ between patients with iPAH and controls ( Figures 6C and 6D ).
Treatment of P-ECs with Ang1 at increasing concentrations of 1, 5, 10, 50 and 100 ng/mL induced a dose-dependent increase of 5-HT concentrations in the medium of P-ECs from both patients with iPAH and controls. This occurred although the ratios of 5-hydroxyindoleacetic acid (5-HIAA) over 5-HT before and after Ang1 treatment remained unchanged in patients with iPAH (59±12% vs. 63±14%, respectively; NS) and in controls (50±8% vs. 52±7%
respectively; NS). In contrast, Ang1 treatment increased the ET-1 concentration only in the medium of P-ECs from patients with iPAH, the effect being greatest with an intermediate Ang1 dose. Ang1 did not affect EGF or PDGF-BB concentrations in culture media of P-ECs from either patients with iPAH or controls ( Figures 6C and 6D ).
DISCUSSION
The present study of P-ECs and PA-SMCs from patients with iPAH and controls shows that the angiopoietin/Tie2 pathway contributes to PA-SMC proliferation by stimulating the release of growth factors by P-ECs. Although the stimulating effect of P-EC media on PA-SMC growth was greater with P-ECs from patients with iPAH than from controls, treatment with Ang1 in both cases stimulated the PA-SMC growth-promoting activity of P-EC media.
We found that Ang1 expression in PA-SMCs did not differ between patients with iPAH and controls, whereas the Ang1 receptor Tie2 was overexpressed in P-ECs from patients with iPAH. Consequently, stimulation by Ang1 of PA-ECs from patients with iPAH increased the release of the signaling molecules 5-HT and ET-1, which was less marked in P-ECs from controls. Taken together, these results suggest that the Ang1/Tie2 pathway is abnormal in iPAH and contributes to PA-SMC hyperplasia.
The present study builds on our previous finding that cultured P-ECs constitutively produce and release growth factors that act on PA-SMCs 11 . During development, factors derived from endothelial cells participate in blood vessel formation and maturation by recruiting and stabilizing vascular wall cells 18 . Because this maturation phase of angiogenesis is known to be under the control of Ang1, one current hypothesis is that the angiopoietin pathway may be abnormal in PAH 10, 19, 20 , leading to excessive smooth muscle proliferation.
Evidence for this hypothesis is lacking, however. In previous studies, we found that serumfree medium of quiescent P-ECs elicited marked PA-SMC proliferation, and that this effect was greater with P-ECs from patients with iPAH than from controls 11 . Because these results
were obtained without stimulating P-ECs with Ang1, we reasoned that the excessive release of growth factors seen in P-ECs from iPAH patients was due to an intrinsic P-EC abnormality independent from Ang1 stimulation. However, in the present study, we found that stimulation of PA-SMC proliferation by culture medium from P-ECs was more marked when P-ECs were pretreated with Ang1, whether the P-ECs were from controls or from patients with iPAH.
Together with the results obtained by Sullivan et al in rat SMCs 10 , these observations strongly support a physiological role of Ang1 in the pulmonary circulation involving stimulation of PECs to release growth factors that act on PA-SMCs. The physiological importance of these observations is also supported by the fact that the proliferation-promoting effect of Ang1 occurred at doses previously shown to induce Tie2 receptor signaling, EC migration, decreased EC permeability, and protection against EC apoptosis [21] [22] [23] [24] .
The Ang1/Tie2 pathway has been reported to be abnormal in PAH. Ang1 was overexpressed in proportion to pulmonary vascular resistance in patients with various forms of PAH 19 . Moreover, increased Ang1 expression was found in piglets with high-flow-induced PAH 25 . In the present study, no increase was noted in Ang1 mRNA or protein in lung tissue or PA-SMCs from patients with iPAH, in comparison with controls. The reasons for these apparently discrepant results are not clear. An important point is that, in contrast to results reported by Du et al who failed to detect Ang1 in samples from normal subjects 19 , we detected significant amounts of Ang1 in lungs and PA-SMCs from our control subjects. Moreover, in our 14 iPAH patients, we found no correlation between iPAH severity and Ang1 levels, in contrast to the findings by Du et al. It is also important to point out that Ang1 expression in the present study was assessed on isolated cultured PA-SMCs, in the absence of mechanical stress or pharmacological influences, and that the PA-SMCs were from patients with strictly defined iPAH. Our results therefore strongly suggest that Ang1 expression may remain unchanged in the majority of patients with advanced iPAH.
In contrast to the absence of changes in lung Ang1 expression, Tie2 receptor expression was increased in lungs and cultured P-ECs from patients with iPAH compared to controls. This overexpression of Tie2 was conserved in cultured P-ECs, in the absence of possible confounding influences by in vivo hemodynamic conditions, therapies, or 16 concomitantly expressed mediators. One expected effect of Tie2 activation in P-ECs is increased release of factors that promote the recruitment and proliferation of vascular wall cells. To investigate this possibility, we evaluated the consequences of Tie2 activation by Ang1 on the release of ET-1, 5-HT, PDGF-BB, and EGF by P-ECs. The last two growth factors were chosen because PDGF-BB is known to play a critical role in the recruitment of pericytes to newly formed vessels 26, 27 and because EGF has been shown to undergo upregulation in response to Ang1 in endothelial cells 28 . In the present study, however, neither PDGF-BB nor EGF was affected by stimulating Tie2 with Ang1, whether the P-ECs were from patients with iPAH or from controls. Moreover, basal growth-factor release by P-ECs did not differ between patients with iPAH and controls. In contrast, and as previously demonstrated, ET-1 and 5-HT concentrations in media of quiescent P-ECs from patients with iPAH were markedly higher than in those from controls 11 . Stimulation with Ang1 further increased the release of ET-1 and 5-HT from P-ECs of patients with iPAH, whereas in P-ECs from controls it stimulated only the release of 5-HT. The 5HIAA/5-HT ratio remained unchanged, indicating that the 5-HT increase was not due to altered indoleamine degradation.
Ang1 also increased the mRNAs encoding preproendothelin-1, ECE-1, and TPH1 in P-ECs from patients with iPAH but not in those from controls. These results are in accordance with those obtained by Sullivan et al showing that Ang1 stimulated 5-HT release by P-ECs 10 . The biphasic effect of Ang1 on ET-1 levels is consistent with previous studies showing increased NO formation with high Ang1 doses 29 . Here, we show that the increased 5-HT release induced by Ang1 occurred together with increased expression of TPH1, the rate-limiting enzyme of 5-HT synthesis. Moreover, Ang1 also stimulated the release of ET-1 as a result of increased expression of ECE1, and to a lesser extent, preproET-1. It is noteworthy that the basal levels of the two mediators stimulated by Ang1 in P-EC media, namely, 5-HT and ET-1, differed between patients with iPAH and controls, whereas those of PDGF and EGF, which
were not upregulated by Ang1, were similar in patients and controls. A link between these alterations and Tie2 overexpression in P-ECs from patients with iPAH is unlikely, since basal 5-HT and ET-1 levels were measured in the absence of Tie2 activation by Ang1. Of note is the fact that Ang1 is mostly synthesized by smooth muscle cells, whereas Ang2, which works as an antagonist of Tie2 receptor, is mostly synthesized by endothelial cells. Thus, it is unlikely that endogenous Ang1 contributed in our in vitro system to activate Tie2 receptors.
Whatever the case, the present results provide evidence that the Ang1/Tie2 pathway is altered in patients with iPAH in a way that leads to excessive release of potent factors involved in the contraction and remodeling of pulmonary blood vessels, namely, 5-HT and ET-1.
In our previous study investigating the cross-talk between P-ECs and PA-SMCs, we found that 5-HT accounted for 60% of the growth-promoting effect of P-EC media on PA-SMC, with no contribution of ET-1 11 . Because the mitogenic action of 5-HT on PA-SMCs is mediated by its selective transporter (5-HTT) 12 , we determined whether the increased growth activity of P-EC media induced by Ang1 was abolished by treating the PA-SMCs with fluoxetine, a selective 5-HTT inhibitor. Fluoxetine dramatically reduced the growthpromoting effect of P-EC media on PA-SMCs under all study conditions but did not abolish the stimulating activity of Ang1. Moreover, in the presence of fluoxetine, PA-SMC proliferation induced by EC medium from patients with iPAH remained slightly higher than the proliferation induced by EC medium from controls in the absence of fluoxetine. These results indicate that Ang1 stimulated growth factors other than 5-HT, which largely contributed to the growth-promoting activity of the P-EC medium. It is therefore likely that pathways other than those mediated by 5-HT are involved in the proliferative response of PASMCs to P-EC media and that Ang1 stimulates several of these pathways, thereby contributing to pulmonary vessel muscularization. It is also likely that EC-SMC cross-talk involving 5-HT is unique to the pulmonary circulation, since TPH expression seems lower in systemic-vessel endothelial cells than in pulmonary vessels, and since 5-HT does not seem to exert potent mitogenic effects on SMCs in systemic vessels 30, 31 .
Because the present findings were obtained from in vitro studies, they do not readily allow definite conclusions about the role of angiopoietins in the pulmonary hypertension process. In accordance with the proposal that the Ang1/Tie2 pathway contributes to pulmonary vascular remodeling, rats engineered to overexpress Ang1 in the pulmonary circulation developed severe pulmonary hypertension with prominent medial hypertrophy 10, 20 .
Moreover, rats expressing a soluble inactive form of the Tie2 receptor were protected against monocrotaline-induced PAH 32 . In contrast, administration of cells expressing Ang1 to monocrotaline-treated rats was shown to induce protection against the development of pulmonary hypertension 33 . One aspect not completely clarified in the present study is that the final effects of Ang1 in vivo also depend on the action of the Tie2 antagonistic ligand Ang2.
Indeed, Ang2 has been identified as a functional antagonist of Ang1, and one established concept is that Tie2 receptor activation in vivo results from the delicate balance between Ang1 and Ang2 levels. In the present study, we found that lung Ang2 and Ang1 protein levels did not differ between patients with iPAH and controls, suggesting that the balance was not affected by iPAH. However, Ang1 is expressed chiefly by PA-SMCs and acts in a paracrine fashion, whereas Ang2, which is expressed mainly by ECs and stored in Weibel-Palade bodies, acts via an autocrine mechanism. Although higher levels of lung phosphorylated Tie2 in patients with iPAH argue for increased in vivo activation of the receptor, it is difficult to extrapolate our in vitro findings to in vivo effects of angiopoietins in human iPAH. Moreover, Ang1 has many biological functions, including inhibition of endothelial apoptosis, which may protect the pulmonary vasculature under some experimental conditions. Ang1 has been reported to exert antiinflammatory effects 22, 34, 35 in addition to regulatory effects on vessel maturation and vascular quiescence. On the other hand, Ang2 was recently shown to sensitize endothelial cells to TNF-alpha and to play a crucial role in the induction of inflammation 36 .
Further studies are therefore needed to better delineate the exact role played by Ang1 in experimental and human PAH.
In the present study of human tissues, we obtained evidence that the angiopoietin-1/Tie2 pathway was abnormal in iPAH and contributed to PA-SMC hyperplasia through excessive release of growth factors by P-ECs. Since Ang1 is now considered a pericyte- 
